Compare TCRT & RVYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCRT | RVYL |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 9.3M |
| IPO Year | N/A | N/A |
| Metric | TCRT | RVYL |
|---|---|---|
| Price | $3.38 | $0.17 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 63.3K | ★ 1.9M |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $6,000.00 | ★ $48,858,000.00 |
| Revenue This Year | $5,680,500.00 | N/A |
| Revenue Next Year | N/A | $297.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 29.50 |
| 52 Week Low | $1.31 | $0.17 |
| 52 Week High | $6.20 | $2.33 |
| Indicator | TCRT | RVYL |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 29.40 |
| Support Level | $3.31 | $0.20 |
| Resistance Level | $4.50 | $0.30 |
| Average True Range (ATR) | 0.37 | 0.03 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 22.83 | 6.45 |
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.